Abstracts tagged "Biologicals"

Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Anna Molto¹, aya ajrouche², Diep Tran², Nathalie Costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁵, Bruno Fautrel⁷ and Florence Tubach², ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴APHP, Paris, France, ⁵Paris-Cité University, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Sorbonne Université APHP, Paris, France
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…
Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Panagiotis garantziotis¹, Georgia-Savina Moysidou², stavros doumas³, Dionysis nikolopoulos², Sofia Flouda⁴, Noemin kapsala², Anastasia Filia², George Sentis², Antonis Fanouriakis², George Bertsias⁵ and Boumpas Dimitrios⁶, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴Unit of Attikon University Hospital, Athens, Greece, ⁵Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1179 • ACR Convergence 2023
Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome
Javier Narvaez¹, Elena Cañadillas-Sanchez², Ivan Castellvi³, Juan José Alegre⁴, Paola Vidal-Montal⁵ and Joan Miquel Nolla⁵, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Department of Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and interstitial lung disease (ASS-ILD). Methods:…
Abstract Number: 1382 • ACR Convergence 2023
Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Qinghong Liu¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by systemic involvement and lacks effective treatment options. The Janus kinase (JAK) pathway plays a…
Abstract Number: 1512 • ACR Convergence 2023
Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Khaled Mahmoud, Michelle Wilson, Md Yuzaiful Md Yusof, Sarah Brown, Elizabeth Hensor and Ed Vital, University of Leeds, Leeds, United Kingdom
Background/Purpose: New medicines in SLE have not met endpoints in placebo-controlled RCTs when other evidence indicates they are effective. Reasons suggested are inclusion of patients…
Abstract Number: 1982 • ACR Convergence 2023
Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis
Terence O'Neill¹, Matthew Parkes¹, Michael Bowes², Richard Hodgson¹ and David Felson³, ¹University of Manchester, Manchester, United Kingdom, ²Imorphics, Manchester, United Kingdom, ³Boston University, Boston, MA
Background/Purpose: There are currently no licensed therapies which reduce progression of knee OA. Current therapies focus on reducing pain, have limited effect, and some have…
Abstract Number: 2199 • ACR Convergence 2023
Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration
Marion Pons¹, Stylianos Georgiadis¹, Zohra Faizy Ahmadzay², Mikkel Østergaard³, Bente Glintborg¹, Jette Heberg¹, Sara Nysom Christiansen¹, Simon Horskjær Rasmussen¹, Isabel Castrejon⁴, Fernando Alonso⁵, Karin Laas⁶, Sigrid Vorobjov⁷, Nikita Khmelinskii⁸, Jakub Zavada⁹, Adrian Ciurea¹⁰, Michael Nissen¹¹, Brigitte Michelsen¹², Pawel Mielnik¹³, Anne Gitte Loft¹⁴, Ziga Rotar¹⁵, Katja Perdan Pirkmajer¹⁶, Gary Macfarlane¹⁷, Gareth T. Jones¹⁷, Dan Nordstrom¹⁸, Anna-Mari Hokkanen¹⁹, Irene van der Horst-Bruinsma²⁰, Johan Karlsson Wallman²¹, Bjorn Gudbjornsson²², olafur Palsson²³, Merete Hetland¹ and Lykke Ørnbjerg¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ⁷National Institute for Health Development, Tallinn, Estonia, ⁸Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁹Institute of Rheumatology; Charles University, Prague, Czech Republic, ¹⁰University Hospital Zurich, Zürich, Switzerland, ¹¹Geneva University Hospitals, Geneva, Switzerland, ¹²Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹³Section for Rheumatology, Helse Førde, Førde, Norway, ¹⁴Aarhus University, Horsens, Denmark, ¹⁵University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ¹⁷Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹⁸Helsinki University Hospital, Helsinki, Finland, ¹⁹Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ²⁰Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²¹Lund University and Skåne University Hospital, Lund, Sweden, ²²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²³Faculty of Medicine, University of Iceland, Reykjavik, Iceland
Background/Purpose: Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are part of the spondylarthritis spectrum that can be treated with secukinumab, a fully human IgG1 monoclonal…
Abstract Number: 2254 • ACR Convergence 2023
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng², Ruru Guo³ and Bharat Kumar⁴, ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²The Wright Center for Graduate Medical Education, Scranton, PA, ³Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
Abstract Number: 2542 • ACR Convergence 2023
Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jin Hyun Kim⁴ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Ajou University School of Medicine, Suwon, South Korea, ⁴Chungnam National University College of Medicine, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea
Background/Purpose: Recent randomized-controlled studies have suggested that tapering bDMARDs and/or csDMARDs after achieving sustained remission in patients with rheumatoid arthritis (RA) can be considered. However,…
Abstract Number: 0378 • ACR Convergence 2023
Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment
Remco Erkens¹, Laura Huber¹, Anouk Verwoerd¹, Greta Rogani¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Wineke Armbrust³, Elizabeth Legger⁴, Sylvia Kamphuis⁵, Ellen Schatorjé⁶, Esther Hoppenreijs⁷, Joost Swart⁸, Marc Jansen¹, Jorg van Loosdregt¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University Medical Hospital Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁶University Medical Center Radboud, Nijmegen, Netherlands, ⁷Radboud University Medical Center, Nijmegen, Netherlands, ⁸Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe inflammatory disease with auto-inflammatory characteristics. The introduction of targeted biologic therapies has revolutionized the treatment and…
Abstract Number: 0498 • ACR Convergence 2023
Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Arad Dotan¹, Niv Ben-Shabbat¹, Abdulla watad², Dennis McGonagle³ and Howard AMITAL², ¹Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Major adverse cardiovascular events (MACE) are known comorbidities and consequences of psoriasis (PsO) and psoriasis arthritis (PsA). Previous studies underlined the potential of immunomodulatory…
Abstract Number: 0595 • ACR Convergence 2023
Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Gelareh Atefi⁶, Gary Bryant⁶, Micki Hultquist⁷, Raj Tummala⁷, Gabriel Abreu⁸, Catharina Lindholm⁸ and Hussein Al-Mossawi⁹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, nephritis is present in 50%–60% during the first 10 years of disease.1 Renal involvement is associated with poor clinical outcomes…
Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…
Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Fahad Ahmed¹, Syed M. Rahman², Sarah Trent³, Lap Pham³, Nashwah Memon⁴, Hannah Chung³ and Adel Haque⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³PA Dermatology Partners, Philadelphia, PA, ⁴Lake Erie College of Osteopathic Medicine, Bradenton, FL, ⁵Jefferson Health - Northeast, Philadelphia, PA
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].